MS and Demyelinating Disorders

Here's what is coming soon to NeurologyLive.

The neurologist from Banner Health and chief medical officer of the MS Association of America discussed how much a patients prognosis plays into the treatments utilized.

Experts in the field of multiple sclerosis provide insight into the fumarates as a viable oral option for relapsing MS.  

A panel of experts discuss the use of anti-CD20 monoclonal antibodies in relapsing multiple sclerosis including summaries of the phase III ORATORIO and ASCLEPIOS trials, for ocrelizumab and ofatumumab, respectively.

Neurology News Network for the week ending July 24, 2021.

Investigators evaluated the occurrence of multiple sclerosis and neuromyelitis optica spectrum disorder in Australian and New Zealand Indigenous populations, comparing data with ancestral data.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 23, 2021.

While rituximab treatment puts patients at a higher risk for infectious disease in general, use of such treatment poses particular risk for severe COVID-19 infections in patients with MS.

Ahmed Obeidat, MD, PhD; Francois Bethoux, MD; and Nicholas C. Ketchum, MD, discuss recent advancements and future directions in rehabilitation strategies for multiple sclerosis.

The associate professor of neurology at Mayo Clinic Rochester discusses technological advancements and research efforts in relation to differential multiple sclerosis.

The majority of tests with the tool correlated with Expanded Disability Status Scale scores, 29-item Multiple Sclerosis Impact Scale items or subscales scores, and/or normalized brain volume measures.

The associate professor of neurology at Mayo Clinic Rochester, commented on biomarkers for identifying MS in patients, as well as the significance of new MS consensus guidelines.

Data suggest a link between different disease-modifying strategies and the occurrence of depression when treating patients with MS.

The neurologist from Banner Health and chief medical officer of the MS Association of America discussed the ongoing debate of when to administer high efficacy treatments throughout the MS disease progression.

The development of agents for MS to address the treatment needs of patients with progressive and relapsing disease has been an ongoing effort that has brought forth a few new potential disease-modifying therapies.

The associate professor of neurology at Mayo Clinic Rochester discusses the importance of alternative diagnoses and rarer presentations of MS, in order to avoid misdiagnoses and inappropriate treatment for patients.

Instead of a smooth-contoured, thin, and regular ring or arc typically seen, pattern 3 patients had atypical rings such as irregularly thick rings and arcs.

Here's what is coming soon to NeurologyLive.

Following the development and publication of consensus guidelines for the use of MRI in MS, Scott D. Newsome, DO, discusses next steps in adopting and implementing protocols to improve patient care.

Expert neurologists discuss the role of sphingosine-1-phosphate (S1P) receptor modulators in relapsing multiple sclerosis including vaccine considerations and pediatric use.

Key opinion leaders provide insight into the use cladribine for relapsing multiple sclerosis including durability and safety profile.

Orelabrutinib has the potential to inhibit B cell and myeloid cell effector functions in the central nervous system and may provide a clinically meaningful benefit on progression in all forms of MS.

Neurology News Network for the week ending July 17, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 15, 2021.

In discussion regarding the new MRI consensus guidelines for patients with MS, Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss key points for their peers and colleagues.